Compare Gitlab Inc (GTLB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Neurocrine Biosciences Inc — how do they compare? Gitlab Inc trades at $31.78 (market cap $5.54B), while Neurocrine Biosciences Inc trades at $171.47 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is far larger — about 3.1× Gitlab Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| GTLB | NBIX | |
|---|---|---|
Market Cap | $5.54B | $17.30B |
Sector | Technology | Health |
52-Week High | $51.04 | $180.55 |
52-Week Low | $19.42 | $123.10 |
Enterprise Value | $4.29B | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab trades at $31.50, down 4.49% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $759.25M in 2025, though net income remained negative at -$6.33M. Recent earnings beats and a strategic position in AI-driven DevSecOps, including a fourth consecutive Gartner Magic Quadrant leadership recognition (Business Wire, 2026-06-17), highlight growth potential despite profitability challenges.
The outlook balances strong revenue growth and market position against high valuation multiples and persistent losses. Analyst consensus targets $32.50, suggesting modest upside, but risks include execution on profitability and competitive pressures in the software sector. Cash flow trends show improvement projected for 2026, yet investor caution is warranted given the elevated P/E ratio of 521.22.
Neurocrine Biosciences (NBIX) trades at $171.81, down slightly by 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, and robust profitability metrics like a 98.17% gross margin. Recent news highlights pipeline advancements and a Zacks upgrade to Strong Buy, reflecting positive sentiment.
Outlook remains positive with a consensus price target of $195.75, implying 14% upside. Key opportunities include sustained revenue growth and pipeline progress, while risks involve execution on recent acquisitions and competitive pressures. The stock is well-positioned for momentum but requires monitoring of Q2 2026 results due July 30.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
